A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)

drug protocol number
D9670C00001
drug sponsor
Astrazeneca
drug study
Trastuzumab Deruxtecan
drug trial site
King Fahad Medical City (Riyadh)
drug status
Ongoing
drug phase